MYC and plasma cell myeloma: Treatment with the benzodiazepine-derived inhibitor JQ1 recapitulated anti-leukemic effects of shRNA-induced suppression of BRD4 in several AML cell lines, mouse models and primary patient samples [2], and has also been associated with potent cell growth inhibition, cell cycle arrest and cell senescence, and decrease of c-MYC in three murine multiple myeloma cell lines [4].